{"entity":{"id":"immix-biopharma","kind":"company","name":"Immix Biopharma","aka":["Immix Biopharma, Inc.","Nexcella","NASDAQ:IMMX"],"tldr":"Immix Biopharma is a Los Angeles cell-therapy company whose BCMA CAR-T NXC-201 is the first CAR-T to show deep responses in AL amyloidosis, the disease in which misfolded antibody fragments damage the heart and kidneys.","summary":"Immix Biopharma, through its subsidiary Nexcella, develops NXC-201 (formerly HBI0101), a BCMA-directed CAR-T cell therapy originally created at Hadassah Medical Center in Jerusalem. NXC-201 is being studied in the NEXICART-2 trial in relapsed or refractory AL amyloidosis, where it holds orphan and regenerative medicine advanced therapy designations, and in multiple myeloma. The company also has the tissue-specific therapeutic IMX-110 for soft tissue sarcoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.immixbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["nxc-201-car-t"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Los Angeles, California","country":"US","companyType":"cell-therapy","website":"https://www.immixbio.com/","ticker":"NASDAQ:IMMX","founded":2012,"stage":"public","investors":[],"funding":[]},"route":"/companies/immix-biopharma/","neighbours":{"drug":[{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/"}]}}